Latest Revenue Guidance News

AVITA Medical reported a robust 67% increase in first quarter 2025 revenue, driven by new product launches and a strategic commercial overhaul, while reaffirming its full-year growth and profitability targets.

Chrysos Corporation reported a 25% year-on-year revenue increase in Q3 FY25, driven by strong growth in sample volumes and expanded deployment of its PhotonAssay technology across key mining regions.

Motio Limited has upgraded its FY25 financial guidance following robust trading after the April period, raising revenue and cash EBITDA targets while maintaining a solid cash position.

DXN Limited reported a modest 2% revenue increase to $2.5 million in Q3 FY25, launched its Data Centre as a Service division with a $3.6 million initial contract, and progressed a key acquisition valued at $10 million, positioning itself for growth despite some project delays.

Genesis Resources has completed its acquisition of full ownership of the Plavica JV in North Macedonia and is progressing environmental studies and exploration planning for multiple Australian tenements ahead of 2025 drilling campaigns.

Microba Life Sciences reported robust Q3 FY25 growth in its microbiome diagnostic tests, led by MetaXplore and MetaPanel, while advancing its therapeutics pipeline and projecting strong full-year revenue growth.

Microba Life Sciences reports robust growth in microbiome diagnostic testing across Australia and the UK, while advancing US market entry plans and transitioning its Therapeutics business to a partnering model.

Fluence Corporation reported a robust Q1 2025 with revenue surging 64.5% year-over-year, driven by the Ivory Coast Addendum project, while EBITDA turned positive for the first time in over a year. The company maintains its full-year guidance despite tariff uncertainties.

Fluence Corporation Limited reported a robust 64.5% revenue increase in Q1 2025, driven by a strategic pivot to higher-margin Smart Product Solutions and recurring revenue streams, while maintaining its full-year guidance.

Nova Eye Medical reported a 27% rise in Q3FY25 sales excluding China, driven by record US performance and a sharp reduction in glaucoma segment losses. The company confirmed FY25 revenue guidance and unveiled plans to expand its iTrack™ technology into ocular drug delivery.

Aroa Biosurgery reports a second consecutive quarter of positive operating cash flow and record sales for its Myriad product line, while maintaining full-year FY25 revenue and EBITDA guidance.

Atturra Limited reports a robust first half of FY25 with revenue growth nearing 28%, driven by recent acquisitions and expanding service offerings, while updating full-year guidance amid cautious government sector risks.